- Home
- MBRX vs CLGN Comparison
MBRX vs CLGN Comparison
Compare MBRX & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- CLGN
- Stock Information
- Founded
- MBRX 2015
- CLGN 2004
- Country
- MBRX United States
- CLGN Israel
- Employees
- MBRX N/A
- CLGN N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- MBRX Health Care
- CLGN Health Care
- Exchange
- MBRX Nasdaq
- CLGN Nasdaq
- Market Cap
- MBRX 17.1M
- CLGN 19.1M
- IPO Year
- MBRX 2016
- CLGN N/A
- Fundamental
- Price
- MBRX $0.68
- CLGN $2.55
- Analyst Decision
- MBRX Strong Buy
- CLGN Strong Buy
- Analyst Count
- MBRX 3
- CLGN 2
- Target Price
- MBRX $5.33
- CLGN $11.50
- AVG Volume (30 Days)
- MBRX 2.6M
- CLGN 42.5K
- Earning Date
- MBRX 08-12-2025
- CLGN 08-20-2025
- Dividend Yield
- MBRX N/A
- CLGN N/A
- EPS Growth
- MBRX N/A
- CLGN N/A
- EPS
- MBRX N/A
- CLGN N/A
- Revenue
- MBRX N/A
- CLGN $2,472,000.00
- Revenue This Year
- MBRX N/A
- CLGN $1,999.42
- Revenue Next Year
- MBRX N/A
- CLGN $69.81
- P/E Ratio
- MBRX N/A
- CLGN N/A
- Revenue Growth
- MBRX N/A
- CLGN N/A
- 52 Week Low
- MBRX $0.25
- CLGN $1.31
- 52 Week High
- MBRX $3.65
- CLGN $5.45
- Technical
- Relative Strength Index (RSI)
- MBRX 53.28
- CLGN 54.66
- Support Level
- MBRX $0.62
- CLGN $2.60
- Resistance Level
- MBRX $0.70
- CLGN $3.23
- Average True Range (ATR)
- MBRX 0.07
- CLGN 0.30
- MACD
- MBRX -0.00
- CLGN -0.01
- Stochastic Oscillator
- MBRX 61.43
- CLGN 37.54
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.